Talk:Progress and Prospects in Parkinson's Research/Hot Topics

I suggest we start a list of topics here that could be elaborated into Hot Topics.

Topic	Example Instances	Links
Genetics
	23&Me	http://www.capradio.org/news/npr/story?storyid=158943097
	Mennonite gene DNAJC13	http://www.sciencedaily.com/releases/2012/06/120627131936.htm, http://www.sciencecodex.com/parkinsons_disease_gene_identified_with_help_of_mennonite_family_ubcvch_research-94062
	FOXO1	http://www.sciencedaily.com/releases/2012/06/120629142609.htm, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386245/
	LRRK2	http://medicalxpress.com/news/2012-05-blocking-lrrk2-simple-parkinson-disease.html, http://www.molecularneurodegeneration.com/content/pdf/1750-1326-7-25.pdf
Non-notor
Existing drugs
	Apomorphine
	Ropinirole implants	http://www.marketwatch.com/story/titan-completes-preclinical-study-of-a-continuous-dopamine-agonist-treatment-for-parkinsons-disease-2012-07-09
	Inhaled levodopa phase 2	http://www.marketwatch.com/story/civitas-therapeutics-initiates-phase-2a-clinical-study-of-cvt-301-an-inhaled-l-dopa-for-parkinsons-disease-2012-06-15
	Latrepirdine	http://www.ncbi.nlm.nih.gov/pubmed/22869031
Caffeine		http://www.cbsnews.com/8301-504763_162-57484791-10391704/caffeine-from-two-to-four-daily-cups-of-coffee-may-reduce-parkinsons-disease-symptoms/
Anti-inflammatories
	anti-cytokines	http://www.jneurosci.org/content/32/30/10201.abstract?sid=864d8c7c-49b2-416d-996d-bc668e978038
	Triterpenoids boost Nrf2	http://www.sciencedaily.com/releases/2012/07/120723134755.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed:+sciencedaily/health_medicine/parkinsons_disease+(ScienceDaily:+Health+&+Medicine+News+--+Parkinson's+Research), http://www.ncbi.nlm.nih.gov/pubmed/22746536
Risk factors for PD
	Family member	http://www.familypracticenews.com/news/more-top-news/single-view/family-history-tops-parkinson-s-disease-risk-factors/46665e2ae4daab3b55054aa8e8d65106.html
	Flu	http://india.nydailynews.com/business/9b1d626c4fd9d5c80501387b88098d07/severe-flu-doubles-odds-of-developing-parkinson-s, http://india.nydailynews.com/business/9b1d626c4fd9d5c80501387b88098d07/severe-flu-doubles-odds-of-developing-parkinson-s
Diagnosis, biomarkers
Alpha-Synuclein
iPSCs
Neuroprotection
	XP23829, a fumaric acid ester	http://www.marketwatch.com/story/xenoport-awarded-grant-from-the-michael-j-fox-foundation-to-examine-xp23829-in-preclinical-models-of-parkinsons-disease-2012-07-11
	isradipine	https://foxtrialfinder.michaeljfox.org/newsletter/1/#1
	rapamycin	http://www.sciencedaily.com/releases/2012/06/120629211902.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed:+sciencedaily/mind_brain/neuroscience+(ScienceDaily:+Mind+&+Brain+News+--+Neuroscience),http://www.ncbi.nlm.nih.gov/pubmed/22750207
DBS and rTMS
	DBS Long term benefits	http://www.webmd.com/parkinsons-disease/news/20120620/device-calms-parkinsons-tremor-3-years
	rTMS	http://www.sciencealert.com.au/news/20121107-23561.html, http://www.ncbi.nlm.nih.gov/pubmed/22881826
Open Access to publicly funded research results		http://www.guardian.co.uk/science/2012/jul/15/free-access-british-scientific-research
Example	Example	Example

• BBC News: "Range of brain diseases could be treated by single drug". http://www.bbc.co.uk/news/health-17952797. Protein misfolding disease cause a similar disruption of the protein translation mechanism which can be 'switched back on'.
  • Source: Moreno, Julie A., Helois Radford, Diego Peretti, Joern R. Steinert, Nicholas Verity, Maria Guerra Martin, Mark Halliday, et al. “Sustained Translational Repression by eIF2[agr]-P Mediates Prion Neurodegeneration.” Nature (May 6, 2012). http://www.nature.com/nature/journal/vaop/ncurrent/full/nature11058.html.

Droflet (talk) 10:52, 28 May 2012 (UTC)

What do we Know? (Suggestions for Hot Topics)

The following was added to the resource page by ‎User:Reverett123. I have moved them here and shall explain the reasons for doing this and give as much help as possible on his/her talk page at User_talk:Reverett123

Droflet (talk) 11:45, 6 October 2012 (UTC)

. What Do We Know?

II. Systems Interacting in Parkinson’s Disease

A. Immune System B. Endocrine System C. Gastrointestinal System D. Central Nervous System E. Neurotransmitters, Hormones, and Cytokines

III. The Path of Progression of PD

A. Predisposing Factors B. Initiating Triggers

IV. Ongoing Processes

A. Oxidation B. Excitotoxicity C. Mitochondrial Failure D. Neuronflammation and Microglia E. Stress and the HPA F. Autoimmunity

V. Time Periods Related to PD

A. Preconception B. Prenatal C. Prepuberty D. Puberty E. Young Adult F. Mid-Life G. Senior

VI. External Factors and PD

A. Lipopolysaccharide (LPS) B. Pathogens C. Ultrafine Particulates D. Toxins E. Epigenetics

VII. Internal Factors and PD

A. Alpha-Synuclein B. Blood Brain Barrier C. Circadian Rhythms D. Constipation E. Electrolytes and Ion Channels F. Genetics G. Metabolic Factors and Nutrition

VIII. Treatment, Repair, and Cure

A. Therapeutics B. Neurogenesis C. Symptoms

IX. Miscellany

A. Historical View of PD B. Homeostasis C. Related Disorders D. Rhythmic Disruption